Editorial: vedolizumab as a treatment and cause of extra‐intestinal manifestations of inflammatory bowel disease

E-ISSN： 1365-2036|47|4|535-536

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.47, Iss.4, 2018-02, pp. : 535-536

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 4, 2018-02 ,pp. : 485-493

John Wiley & Sons Inc

Access to resources Recommend Favorite

Extraintestinal manifestations of inflammatory bowel disease: Epidemiology, diagnosis, and management

By Larsen Signe Bendtzen Klaus Nielsen Ole Haagen

Annals of Medicine, Vol. 42, Iss. 2, 2010-02 ,pp. : 97-114

Informa Healthcare

Access to resources Recommend Favorite

Modeling the role of genetic factors in characterizing extra-intestinal manifestations in Crohn's disease patients: does this improve outcome predictions?

By Giachino Daniela F. Regazzoni Silvia Bardessono Marco De Marchi Mario Gregori Dario

Current Medical Research and Opinion, Vol. 23, Iss. 7, 2007-07 ,pp. : 1657-1665

Informa Healthcare

Access to resources Recommend Favorite

Intestinal Bacteria and Inflammatory Bowel Disease

By Macfarlane Sandra Steed Helen Macfarlane George

Critical Reviews in Clinical Laboratory Sciences, Vol. 46, Iss. 1, 2009-01 ,pp. : 25-54

Informa Healthcare

Access to resources Recommend Favorite

Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 6, 2018-03 ,pp. : 753-762

John Wiley & Sons Inc

Access to resources Recommend Favorite